Jyong Biotech Ltd. (MENS)
| Market Cap | 608.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.40M |
| Shares Out | 76.03M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MENS
Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms. PCP, our key new drug candidate dev... [Read more]
News
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commerc...
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innova...
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle
Jyong Biotech Ltd. aims to raise $18.8 million in an IPO, but faces significant risks including high debt, legal issues, and FDA approval challenges. The lead drug candidate, MCS-2, has completed Phas...
Jyong Biotech Ltd. Begins U.S. IPO Rollout
Jyong Biotech Ltd. is seeking to raise $40.25 million in an IPO to develop plant-based treatments for urinary system diseases. The company's lead candidate, MCS-2, has completed four phase III trials,...
Urinary disease biotech Jyong Biotech files for a $40 million US IPO
Jyong Biotech, a commercial-stage Taiwanese biotech developing therapies for urinary diseases, filed on Thursday with the SEC to raise up to $40 million in an initial public offering.
Jyong Biotech IPO Registration Document (F-1)
Jyong Biotech has filed to go public with an IPO on the NASDAQ.